1.35
+0.02(+1.50%)
Currency In USD
| Previous Close | 1.33 |
| Open | 1.4 |
| Day High | 1.42 |
| Day Low | 1.32 |
| 52-Week High | 6.77 |
| 52-Week Low | 1.15 |
| Volume | 3.88M |
| Average Volume | 5.08M |
| Market Cap | 213.93M |
| PE | -2.87 |
| EPS | -0.47 |
| Moving Average 50 Days | 1.65 |
| Moving Average 200 Days | 2.26 |
| Change | 0.02 |
If you invested $1000 in Humacyte, Inc. (HUMA) since IPO date, it would be worth $139.61 as of November 11, 2025 at a share price of $1.35. Whereas If you bought $1000 worth of Humacyte, Inc. (HUMA) shares 3 years ago, it would be worth $420.56 as of November 11, 2025 at a share price of $1.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology’s Kidney Week 2025
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
– The ATEV™ was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups with historically poor outcomes with AV fistula procedures – – The significantly longer duration of ATEV use in these high-
Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025
GlobeNewswire Inc.
Nov 06, 2025 1:00 PM GMT
DURHAM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results fo
Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma
GlobeNewswire Inc.
Oct 30, 2025 12:00 PM GMT
- Results published in AAST’s Trauma Surgery & Acute Care Open Journal - - Study compared outcomes of patients treated with Symvess with patients in PROOVIT registry who were treated with vein - - In a comparison to prior results in the PROOVIT regi